Torrent Pharmaceuticals Ltd Company Profile

Torrent Pharmaceuticals Ltd.

Pharmaceutical

Establishment Year
1959
Headquarters
India
Key Management
Mr. Sudhir Mehta (Chairman)
Revenue (US$ Mn)
~ 1,074.8 (2021)
Headcount
~ 13,500 (2021)
Website
www.torrentpharma.com

Business Description

Torrent Pharmaceuticals Ltd. (Torrent), is involved in the development and marketing of new formulations in various therapeutic fields. The company produces and sells pharmaceutical products, both generically and non-branded generic. The company operates in Asia Pacific, Africa, and Europe. Generic Formulation Business is the company’s single segment.

The company manufactures branded formulations. The company manufactures branded formulations. Baddi Plant is where the company produces APIs, including Nicorandil and Risperidone. Torrent also maintains a Sikkim formulation facility, which is located approximately 20 km from Gangtok.

The Sikkim plant produces oral dosage forms. It has several sales and marketing divisions that focus on therapeutic areas. There are 15 divisions in sales and marketing: Prima, Vista, and Sparsh. With over 1200 product registrations, the company exports to more than 40 countries.

The international business of the company is split into the following areas: the US, Latin America, and Russia, as well as the commonwealth of independent states (CIS), Canada, and the UK. Geographically, the company divides its operations into five regions: India, Brazil, Germany, Brazil, Other Countries, and the US. Uttambhai Nathalal Mehta founded the company in 1959. It is headquartered in Ahmedabad in India.

Key Financials

Revenue (US$ Mn)

US$ 1,075 Mn was the annual revenue generated by Torrent Pharmaceuticals Ltd. in 2021
Torrent Pharmaceuticals Ltd.’s annual revenue for 2020 was US$ 892 Mn, a 0.46% increase from 2019
From 2018’s annual revenues, Torrent Pharmaceuticals Ltd. registered a 2.7% increase in 2019, amounting to US$ 887 Mn
Total revenue of US$ 864 Mn was generated in 2018 by Torrent Pharmaceuticals Ltd.

Operating Income (US$ Mn)

Torrent Pharmaceuticals Ltd.’s operating income for 2021 was US$ 241 Mn, a 56.15% increase from 2020
The operating income generated by Torrent Pharmaceuticals Ltd. in 2020 was US$ 154 Mn
At a 24.05% increase from, Torrent Pharmaceuticals Ltd.’s operating income of US$ 130 Mn was indexed in 2019
Torrent Pharmaceuticals Ltd. generated an operating income of US$ 105 Mn in 2018

Net Income (US$ Mn)

US$ 106 Mn was the net income generated by Torrent Pharmaceuticals Ltd. in 2021
Torrent Pharmaceuticals Ltd.’s net income for 2020 was US$ 185 Mn, a 19.84% increase from 2019
From 2018’s net incomes, Torrent Pharmaceuticals Ltd. registered a 17.64% increase in 2019, amounting to US$ 155 Mn
A net income of US$ 132 Mn was generated in 2018 by Torrent Pharmaceuticals Ltd.

Operating Margin %

Torrent Pharmaceuticals Ltd.’s operating margin for 2021 was 21%, a 21.39% increase from 2020
The operating margin generated by Torrent Pharmaceuticals Ltd. in 2020 was 17%
At a 21.49% increase, Torrent Pharmaceuticals Ltd.’s operating margin of 15% was indexed in 2019
Torrent Pharmaceuticals Ltd. generated an operating margin of 12% in 2018

Gross Margin %

Torrent Pharmaceuticals Ltd.’s gross margin for 2021 was 72%, a 0.99% increase from 2020
The gross margin generated by Torrent Pharmaceuticals Ltd. in 2020 was 71%
At a -1.15% decrease, Torrent Pharmaceuticals Ltd.’s gross margin of 69% was indexed in 2019
Torrent Pharmaceuticals Ltd. generated a gross margin of 70% in 2018